C50 C56
Conditions
Interventions
Group 1: Standard care, i.e. the routine care provided in outpatient oncology clinics and practices
Group 2: Pharmaceutical care, i.e. additional patient care by a pharmacist
Sponsors
Pharmazeutisches Institut
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnosis of breast or ovarian cancer, first treatment with chemotherapy, written informed consent, ability to speak, read and write German
Exclusion criteria
Exclusion criteria: Diseases which impeded that the patient completely understood the provided information on the study or if the patient had an impaired capability of reading and completing questionnaires self-administered (e.g. Alzheimer)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete antiemetic response, defined as no emetic episode on five days following chemotherapy, documented in a standardized patient diary | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of emetic episodes and severity of nausea, documented in a standardized patient diary; quality of life, measured using the EORTC QLQ-C30 questionnaire 3 and 6 months after start of chemotherapy; patient satisfaction with information, measured using the PS-CaTE questionnaire 6 months after start of chemotherapy | — |
Countries
Germany
Contacts
Public ContactUlrich Jaehde
Universität Bonn, Abteilung Klinische Pharmazie
Outcome results
None listed